Compare Teladoc Health Inc (TDOC) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Teladoc Health Inc vs 10X Genomics Inc — how do they compare? Teladoc Health Inc trades at $9.69 (market cap $1.74B), while 10X Genomics Inc trades at $47.2 (market cap $5.48B). The key difference: 10X Genomics Inc is far larger — about 3.1× Teladoc Health Inc's market cap. Which is the better fit depends on your goals.
| TDOC | TXG | |
|---|---|---|
Market Cap | $1.74B | $5.48B |
Sector | Health | Health |
52-Week High | $9.72 | $45.80 |
52-Week Low | $4.47 | $11.34 |
Enterprise Value | $2.03B | $5.02B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TDOC trades at $9.71, up 2.97% with a bullish technical signal. The stock shows improving fundamentals with revenue stabilizing around $2.5B and narrowing losses. Recent earnings beat expectations in Q3 and Q4 2025 but missed in Q1 2026. Positive sentiment is driven by partnerships like Walmart Better Care and cost-cutting initiatives, though net margins remain negative.
The outlook suggests cautious optimism as operational improvements may drive recovery, but persistent losses and high debt pose risks. Analyst consensus is mixed with 36% buy ratings and a $9.50 price target, indicating limited upside. Investors should weigh cost-control progress against competitive pressures in telehealth.
TXG trades at $47.20, up 7.91% on the day, with a bullish technical signal from moving averages. The company reported Q1 2026 revenue that beat estimates, and net losses have narrowed significantly from -$255M in 2023 to -$44M in 2025. Operating cash flow turned strongly positive at $136M in 2025. Recent developments include the acquisition of Proteintech Genomics and a collaboration with Cleveland Clinic on bladder cancer diagnostics.
The outlook is mixed; improving fundamentals and strategic expansions support growth, but persistent net losses and a high EV/EBITDA of 133.91 pose valuation risks. Analyst consensus is divided with a $39.14 price target below the current price, indicating caution despite a majority buy/hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Teladoc Health Inc
Teladoc Health is a virtual health provider with a telehealth platform delivering 24-hour, on-demand healthcare via mobile devices, the internet, video, and phone. It also offers remote patient monitoring programs for chronic care management. Its platform connects members with a network of physicians and behavioral health professionals. Most of the company's revenue is generated from access fees on a subscription basis (per member, per month). The balance comes from visit fees and equipment rental and sales to hospital systems. Since inception, Teladoc has primarily partnered with employers, health plans, and health systems to offer network access to their members.
Read more on TDOC →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
